Stay updated on FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.

Latest updates to the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page
- Check6 days agoChange DetectedA funding attribution line '2019 ( U.S. NIH Grant/Contract )' was added, indicating NIH support for the study.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAn updated site revision entry, v3.6.5, has been added, replacing the previous v3.6.4 in the revision history. This reflects a deployment or platform update rather than changes to the study data.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page now displays an updated site revision to v3.6.4, signaling a software patch applied to the ClinicalTrials.gov interface. This update represents an interface-level change rather than a modification to the study data.SummaryDifference0.0%

- Check57 days agoChange DetectedThe page footer now displays Revision: v3.6.3, replacing v3.6.2, indicating a minor UI/version update to the page rendering. It does not modify the study data or how the page operates.SummaryDifference0.0%

- Check64 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2 on the page, reflecting a minor version update to the site's rendering or functionality. This update does not alter study details or other visible content.SummaryDifference0.0%

- Check78 days agoChange DetectedThe page adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment-status note; it also reflects a header labeling change for Intervention/Treatment and a version update to Revision: v3.6.0.SummaryDifference0.3%

Stay in the know with updates to FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.